Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501891 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00501891 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 32 participants.
The verdict
NCT00501891, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a phase II study of the combination of Avastin and metronomic temozolomide in recurrent malignant glioma patients. The primary objective will be to determine the efficacy of Avastin (bevacizumab) and metronomic temozolomide in malignant glioma patients. The secondary objective will be to determine the safety of Avastin, 10 mg/kg every other week, in combination with metronomic temozolomide in terms of progression-free survival.
Interventions
- DRUG Bevacizumab
- DRUG Metronomic Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00501891
The ClinicalTrials.gov registry entry for NCT00501891 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00501891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00501891 about?
NCT00501891 is a clinical study titled "Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma". This is a phase II study of the combination of Avastin and metronomic temozolomide in recurrent malignant glioma patients. The primary objective will be to determine the efficacy of Avastin (bevacizumab) and metronomic temozolomide in malignant glioma patients. The secondary objective will be to det...
What is the current status of trial NCT00501891?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2007-07. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00501891?
The interventions under investigation include: Bevacizumab (DRUG), Metronomic Temozolomide (DRUG).
Who is sponsoring clinical trial NCT00501891?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.